Skip to main content
Figure 2 | BMC Cancer

Figure 2

From: Evaluation of public cancer datasets and signatures identifies TP53 mutant signatures with robust prognostic and predictive value

Figure 2

Kaplan-Meier estimates of distant relapse–free survival analyses of three predictors. 508 patients with HER2- breast cancer from two independent datasets (GSE25055 and GSE25065) were stratified into two groups according to the gene-expression profiles of two genomic predictors (BRmet50 and PMID18271932) and pathologic response (after treatment) such as pathologic complete response (pCR) and residual disease (RD). In each survival plot, two types of distant relapse-free survival retrospectively determined the two genomic predictor group names (treatment-sensitive and treatment insensitive) and were compared: pCR or treatment-sensitive group (solid red line) and RD or treatment-insensitive group (dashed black line). The distant relapse-free time in years is displayed on the x-axis, and the y-axis shows the probability of distant relapse-free survival. The P values indicate the statistical significance of survival time differences between the two groups.

Back to article page